Clinical trials: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Influenza A, Influenza B
Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of…
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT02067286
- Where
- 8 sites in United States
- Volunteers
- 1,642 people
- Sponsor
- IQuum, Inc.
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the seasonal quadrivalent influenza vaccine (FLU-QIV) in adults aged 60…
- Trial name
- NCT04841577
- Testing
- RSVPreF3 OA investigational vaccine, FLU-QIV
- Where
- 14 sites in New Zealand, Panama and 1 more
- Volunteers
- 976 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants
Advanced Vaccine Laboratories Pty Ltd is developing a recombinant Respiratory Syncytial Virus (rRSV) vaccine for the protection of children (6 months to 5 years old) and the elderly from RSV infection.
- Trial name
- NCT04851977
- Testing
- Respiratory Syncytial Vaccine
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
RSV Infection, Bronchiolitis
Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
The fraction of exhaled nitric oxide (feNO) in expired air is a reliable measure of airway inflammation. Some research experiments have demonstrated stimulation of nitric oxide production in respiratory epithelial cells infected…
- Trial name
- NCT01090557
- Testing
- Collection of exhaled breath
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Winthrop University Hospital
Respiratory Syncytial Virus, Bronchiolitis
Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze…
- Trial name
- APW-RSV-II (NCT02911935)
- Testing
- Oral azithromycin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Washington University School of Medicine
Respiratory Syncytial Virus (RSV)
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
- Trial name
- NCT07807449
- Testing
- Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Yikang Biotech (Suzhou) Co., Ltd.
Heart Failure, RSV Infection
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
This prospective, single-centre, open-label, randomized study aims to determine whether coordinated care in administering protective vaccinations (against Respiratory Syncytial Virus (RSV) and influenza) impacts the prognosis of…
- Conditions
- Heart Failure, RSV Infection, Influenza, Vaccines
- Trial name
- VACCINE-CHF (NCT06259487)
- Testing
- Coordinated Vaccination, Following recommendations
- Where
- Poland
- Volunteers
- 250 people
- Sponsor
- Wroclaw Medical University
Respiratory Syncytial Virus Infections
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention…
- Trial name
- NCT07214571
- Testing
- S-337395
- Where
- 89 sites in United States, Argentina and 6 more
- Volunteers
- 192 people
- Sponsor
- Shionogi
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
- Trial name
- NCT02864628
- Testing
- MVA-BN-RSV
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Respiratory Syncytial Virus (RSV)
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and…
- Trial name
- NCT07673081
- Where
- United States
- Volunteers
- 293,334 people
- Sponsor
- Pfizer
Covid19
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease.
- Trial name
- NCT04798001
- Testing
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
- Where
- 2 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Meissa Vaccines, Inc.
Respiratory Syncytial Virus Infections, Virus Diseases
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection after multiple oral doses of JNJ-53718678 at…
- Trial name
- NCT02593851
- Testing
- JNJ-53718678
- Where
- 39 sites in United States, Argentina and 8 more
- Volunteers
- 45 people
- Sponsor
- Janssen Sciences Ireland UC
Respiratory Syncytial Virus Infections
RSV F Dose-Ranging Study in Women
The purpose of this study is to evaluate the immunogenicity and safety of multiple formulations of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy women of child-bearing age.
- Trial name
- NCT01960686
- Testing
- Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant
- Where
- 10 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Novavax
Respiratory Syncytial Virus Infections, Infections, Epidemics
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
The principle purpose of this multicenter trial is to determine the definition, timing and the percentage of nosocomial RSV epidemics throughout Turkey.
- Trial name
- TurkNICU-RSV (NCT01915394)
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people
- Sponsor
- Ankara University
Respiratory Tract Infections
A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)
The purpose of this study is to describe the clinical and economic burden in adults and infants/children less than or equal to 5 years of age by type of respiratory pathogen (respiratory syncytial virus [RSV], influenza A, and…
- Trial name
- NCT03574532
- Where
- 2 sites in Germany, Spain
- Volunteers
- 118 people
- Sponsor
- Janssen-Cilag International NV
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Disease in the Elderly
Respiratory syncytial virus (RSV) causes sickness and deaths in older people every winter. This study will investigate how aging affects the body's immune response (body's response to disease) to RSV.
- Trial name
- NCT00246480
- Where
- United States
- Volunteers
- 1,401 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix…
- Trial name
- NCT05026749
- Testing
- AZM Group, Control Group
- Where
- 15 sites in United States
- Volunteers
- 370 people
- Sponsor
- University of Alabama at Birmingham
Respiratory Syncytial Viral (RSV) Infections
Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) is a leading cause of hospitalizations for acute lower respiratory tract infection (LRTI) in infants.
- Trial name
- NCT06993753
- Where
- Australia
- Volunteers
- 4,350 people
- Sponsor
- Griffith University
Respiratory Syncytial Virus Infection
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
- Trial name
- NCT06904222
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.